1Peterson PN,Masoudi FA.ACE inhibitors for older patients with hear failure:A review of evidence,practice Patterns and challenges[J].Heart Drug,2005 ;5(2):89-99.
2Johnson D,Jin Y,Quan H,et al.Beta-blocker and angiotensin-conyerting enzymeinhibitors/receptor blocker prescription after hospital discharge for heart failure areassiociated with decreased mortality in Alberta,Canada[J].J Am Coll Cardiol,2003 ;42(8):1438-45.
3Masoudi FA,Rathore SS,Wang Y,et al.National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failute and left ventricular Systolic dysfunction[J].Circulation,2004; 110 (6):724-31.
4戴闺柱.β受体阻滞剂开拓了心力衰竭生物学治疗的新纪元.中国医学论坛报,2005,3:1.
5Murphy NF,Simpson CR,McAlister FA,et al.National Survey of the prevalence,incidence,primary care burden,and treatment of hear failure in Scotland[J].Heart,2004 ;90(10):1129-36.
6Stafford RS,Radley DC.The underutilization of cardiac medications of proven beneflt,1990 to 2002[J].J Am Coll Cardiol,2003; 41 (1):56-61.
7Pracker M,Poole-Wilsm PA,Armstrong PW,et al.Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor,lisinopril,on morbidity and mortality in chronic heart failute[J].ATLAS Study Grollp Circutation,1999; 100(23):2312-8.
8Rangaswamy C,Finn JI,Koelling TM.Angiotensin-converting enzyme inhibior use in elderly Patients hospitalized with heart failure and left ventricular systolic dysfunction[J].Cardiology,2005;103 (1):17-23.
9Willenheimer R,Van Veldhuisen DJ,Silke B,et al.Effect on Survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as campared with the opposite sequence,results of the randomized cardiac insufficiency bisoprolol study,(CIBIS)Ⅲ[J].Circulation,2005; 112 (16):2426-35.
1Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation, 2000, 10:484-486.
2De Mey C. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics-observations with beta-adrenoceptor antagonists. Int J Clin Pharmacol Ther, 1997, 35: 453-457.
3Vanhees L, Aubert A, Fagard R, et al. Influence of beta 1- versus beta 2-adrenoceptor blockade on left ventricular function in humans. J Cardiovasc Pharmacol, 1986, 8: 1086-1091.
4De Mey C, Breithaupt-Grogler K, Schloos J, et al. Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. Br J Clin Pharmacol, 1994, 38: 480-483.
5Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. J Card Fail, 2003, 9:429-443.
6Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol, 2000, 35: 45-50.
7Sandberg A, Abrahamsson B, Svenheden A, et al. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing. Pharm Res, 1993, 10:28-34.
